The combination of RMC-4630 and sotorasib was also found to be well tolerated with grade 1 or 2 edema as the most frequent treatment related adverse event (30%) and led to a disease control rate of 64% in patients with NSCLC who were previously treated with a KRAS G12C inhibitor. Here, KRAS is linked to non-small cell lung carcinoma.